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Overexpression of the tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) receptors,
TRAIL-R1 and TRAIL-R2, induces apoptosis and activa-
tion of NF-kB in cultured cells. In this study, we have
demonstrated differential signaling capacities by both
receptors using either epitope-tagged soluble TRAIL
(sTRAIL) or sTRAIL that was cross-linked with a mono-
clonal antibody. Interestingly, sTRAIL was sufficient for
induction of apoptosis only in cell lines that were killed
by agonistic TRAIL-R1- and TRAIL-R2-specific IgG prep-
arations. Moreover, in these cell lines interleukin-6 se-
cretion and NF-kB activation were induced by cross-
linked or non-cross-linked anti-TRAIL, as well as by both
receptor-specific IgGs. However, cross-linking of sTRAIL
was required for induction of apoptosis in cell lines that
only responded to the agonistic anti-TRAIL-R2-IgG. Inter-
estingly, activation of c-Jun N-terminal kinase (JNK) was
only observed in response to either cross-linked sTRAIL or
anti-TRAIL-R2-IgG even in cell lines where both receptors
were capable of signaling apoptosis and NF-kB activation.
Taken together, our data suggest that TRAIL-R1 responds
to either cross-linked or non-cross-linked sTRAIL which
signals NF-kB activation and apoptosis, whereas TRAIL-R2
signals NF-kB activation, apoptosis, and JNK activation
only in response to cross-linked TRAIL.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL),1 also designated as APO-2 ligand, is a member of the
tumor necrosis factor (TNF) family that is capable of inducing
apoptosis in several cell lines (1, 2). TRAIL is widely expressed
in normal cells and is highly homologous to FasL, another
cytotoxic member of the TNF ligand family (1, 2). In addition to
an involvement of TRAIL in natural killer cell-, dendritic cell-,
and CD41 T-cell-mediated cytotoxicity (3–6), TRAIL may also
be involved in monocyte-mediated tumoricidal activity (7) and
activation-induced T cell death during HIV infection (8, 9).
Currently five human TRAIL receptors belonging to the TNF
receptor superfamily have been identified. Two of them,
TRAIL-R1 (DR4, Ref. 10) and TRAIL-R2 (DR5, TRICK2, KILL-
ER; see Refs. 11–18) contain a cytoplasmic death domain and
transmit an apoptotic signal in response to TRAIL. Two other
cellular TRAIL receptors, TRAIL-R3 (TRID, DcR1; see Refs. 11,
14, 17, 19), which is glycosylphosphatidylinositol (GPI)-linked
and TRAIL-R4 (DcR2; see Refs. 20, 21), which contains a trun-
cated death domain, bind TRAIL without activation of the
apoptotic machinery and seem to antagonize the death domain-
containing TRAIL receptors. In addition, osteoprotegerin, a
regulator of osteoclastogenesis, is a soluble receptor for TRAIL
(22). TRAIL-R1- and TRAIL-R2-mediated apoptosis occurs via
activation of caspase-8 and subsequent activation of effector
caspases. However, the link between the death domain-con-
taining TRAIL receptors and activation of caspase-8 is rather
undefined. Transient transfection of TRAIL-R1 leads to activa-
tion of the apoptotic machinery in Fas-associated death domain
protein-deficient fibroblasts, suggesting that FADD, a death
domain adapter molecule, is not required for TRAIL-R1-in-
duced apoptosis (23, 24). On the other hand, overexpression of
a dominant-negative FADD mutant was shown to block
TRAIL-mediated apoptosis (12, 13, 15, 25). It has not yet been
clarified whether FADD plays a specific role in TRAIL-R2-
induced apoptosis or whether a closely related adapter protein
is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis.
Because TRAIL is highly effective in killing cancer cell lines
but has apparently no lethal effects on normal cells, TRAIL and
its apoptotic receptors have attracted much attention as tar-
gets for anti-cancer therapy (26, 27). In this study, we show
that TRAIL-R1 and TRAIL-R2 have different capabilities for
stimulating the JNK pathway and differ also in their cross-
linking requirements for activation by recombinant ligands.
This is the first reported evidence of a difference between
TRAIL-R1 and TRAIL-R2 signaling activities.
EXPERIMENTAL PROCEDURES
Materials—The anti-FLAG monoclonal antibody M2 was purchased
from Sigma-Aldrich (Deisenhofen, Germany). Polyclonal sera specific
for JNK, p65, p50, and cRel were purchased from Santa Cruz Biotech-
nology (Heidelberg, Germany) and protein A-Sepharose was from Am-
ersham Pharmacia Biotech (Freiburg, Germany). The SuperFect trans-
fection reagent was obtained from Qiagen (Hilden, Germany). TRAIL-
R1-Fc and TRAIL-R2-Fc were from Alexis (La¨ufelfingen, Switzerland).
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Cell Lines—HeLa, HepG2, and Jurkat cells were maintained in
RPMI 1640 medium containing 5% (HeLa, HepG2) or 10% (Jurkat)
heat-inactivated fetal calf serum. KB cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum and
HT1080 cells in Dulbecco’s modified Eagle’s medium-nutrient mix F12
containing 10% fetal calf serum. The Kym-1 cell line was maintained in
Click RPMI 1640 medium supplemented with 10% fetal calf serum.
Generation of TRAIL-R1 and TRAIL-R2-specific IgG Preparations—
Using a commercial antibody production service (Eurogentec, Seraing,
Belgium), rabbits were immunized with TRAIL-R1-Fc and TRAIL-R2-
Fc. For antibody purification, TRAIL-R1-Fc and TRAIL-R2-Fc were
coupled to HiTrap N-hydroxysuccinimide (NHS)-Sepharose (Amersham
Pharmacia Biotech, Freiburg, Germany) according to the manufactur-
er’s protocol. Fc-specific antibodies were first depleted by repeated
passages over human IgG1-agarose (Sigma, Deisenhofen, Germany).
TRAIL-R1/R2-specific antibodies were further purified on TRAIL-R1/
R2-Fc-Sepharose, eluted in 50 mM citrate/NaOH, pH 2.7, neutralized
with Tris-HCl, pH 9, and dialyzed against phosphate-buffered saline.
At concentrations below 500 ng/ml, we found no evidence for cross-
reactivity of the anti-TRAIL receptor IgGs even upon secondary cross-
linking with protein A. At higher concentrations (.1000 ng/ml) we
observed a significant cross-reactivity of the anti-TRAIL-receptor IgGs
that could be blocked by addition of TRAIL-R1-Fc to anti-TRAIL-R2 IgG
and vice versa (data not shown).
Cytotoxic Assays—50,000 (Jurkat), 30,000 (HepG2, KB), 20,000
(HeLa, HT1080) or 15,000 Kym-1 cells were grown overnight in 100 ml
of culture medium in 96-well plates. The cells were then treated for 16 h
with FLAG-tagged TRAIL, TRAIL-M2-complex, anti-TRAIL-R1- and
anti-TRAIL-R2-IgG. Cell death assays with HepG2, HeLa, KB, and
HT1080 cells were performed in the presence of 2.5 mg/ml cycloheximide
(CHX). TRAIL-M2-complex was generated by mixing the respective
concentration of FLAG-tagged TRAIL with the anti-FLAG monoclonal
antibody M2 to a final concentration of 1 mg/ml of antibody. After a
15-min incubation at room temperature, the TRAIL-M2-complex was
transferred to the cells. TRAIL-R1 and TRAIL-R2 IgG were added in
the presence of 1 mg/ml protein A (Sigma, Deisenhofen, Germany). Cell
viability was determined using the MTT method (Jurkat, Kym-1) or
crystal violet staining (HepG2, HeLa, KB, HT1080) as described previ-
ously (28, 29).
Immunocomplex JNK Assay—N-terminal c-Jun kinase assays were
performed upon immunoprecipitation of JNK1 using a rabbit antiserum
(Santa Cruz Biotechnology, Heidelberg, Germany). GSTzc-Jun was used
as substrate in an in vitro kinase assay as described previously (30).
Transient Reporter Gene Assays—For transient reporter gene assays,
20,000 HeLa cells were seeded in 96-well tissue culture plates, and the
following day the cells were transfected with a 33 NF-kB-luciferase
reporter plasmid (15% transfected DNA), a SV40 promoter-driven b-ga-
lactosidase expression plasmid (5% transfected DNA) to normalize the
transfection efficiency, and empty vector (80% transfected DNA).
Transfections were performed with SuperFect reagent according to the
manufacturer’s recommendations (Qiagen, Hilden, Germany). After a
1-day recovery, cells were treated with TRAIL, TRAIL-M2-complex,
CHX, and Z-VAD-fmk as indicated, harvested in phosphate-buffered
saline, and then luciferase and b-galactosidase activities were deter-
mined using the Galacto-Light Plus reporter gene assay kit (Perkin
Elmer, Nieuwerkerk, The Netherlands) and a Lucy2 96-well luminom-
eter (Anthos, Krefeld, Germany).
Determination of Interleukin-6 Production—Cells (1.5 3 104 per well)
were seeded in triplicates in 96-well tissue culture plates in 100 ml of
Click RPMI 1640 and cultured overnight. The following day the cells
were treated with the reagents of interest as indicated for an additional
12–24 h. Then the supernatants were removed, cleared by centrifuga-
FIG. 1. Cell type- and response-spe-
cific effects of cross-linked TRAIL-
FLAG. A, the indicated cell lines were
analyzed for their sensitivity to FLAG-
tagged sTRAIL in the presence (filled
squares) or absence (open squares) of ag-
gregating anti-FLAG antibody M2. Cell
viability was determined using the MTT
assay (Jurkat, Kym-1) or by staining ad-
herent cells with crystal violet (HeLa, KB,
HepG2, HT1080). The difference in ab-
sorbance between dead and living cells
was in the range of 600–1000 mOD units
for all cells. B, HeLa and KB cells were
cultured overnight in 96-well plates. Cells
were then incubated for 18 h with the
indicated concentrations of cross-linked
(filled squares) and non-cross-linked
(open squares) sTRAIL-FLAG in the pres-
ence of 2.5 mg/ml CHX and 10 mM Z-VAD-
fmk. Finally, IL-6 concentrations in the
supernatants were determined using a
commercially available ELISA kit. C,
HeLa cells were cultured overnight in 96-
well plates. The next day, cells were
transfected with a 33 NF-kB-luciferase
reporter plasmid and a SV40 promoter-
driven b-galactosidase expression plas-
mid to normalize the transfection effi-
ciency. After an additional day, cells were
stimulated for 9 h with cross-linked (filled
bars) and non-cross-linked TRAIL-FLAG
(open bars) in the presence of CHX (2.5
mg/ml) and Z-VAD-fmk (10 mM). Finally
cells were assayed for NF-kB activation.
D, cell lysates were prepared from HeLa
and Kym-1 cells that had been stimulated
for 4 h with the indicated concentrations of
cross-linked and non-cross-linked TRAIL-
FLAG (TRAIL-F). JNK activity was meas-
ured by immunocomplex kinase assay with
GSTzc-Jun-(1–79) as substrate.
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tion (15,000 rpm, 10 min, 4 °C) and interleukin-6 concentrations were
determined using a commercially available ELISA kit (PharMingen,
Hamburg, Germany).
FACS Staining—Cells were stained for TRAIL-R1, TRAIL-R2,
TRAIL-R3, and TRAIL-R4 expression in 100 ml of FACS buffer (phos-
phate-buffered saline, 5% fetal calf serum, 0.1% NaN3) with 5 mg/ml
anti-TRAIL-R1 mAb M271 (IgG2a), anti-TRAIL-R2 mAb M413 (IgG1),
anti-TRAIL-R3 mAb M430 (IgG1) and anti-TRAIL-R4 mAb M445
(IgG1), respectively, or the respective control IgG, followed by fluores-
cein isothiocyanate-labeled anti-mouse antibody (5 mg/ml). FACS anal-
yses were performed with a FACStar plus instrument (Becton Dickin-
son, San Jose, CA).
EMSA Analysis of NF-kB Activation—HeLa and Kym-1 cells (106)
were seeded in 60-mm cell culture dishes and cultivated overnight to
allow adherence. The next day the cells were stimulated for 3 h with the
indicated combinations of anti-TRAIL-R1 and anti-TRAIL-R2 IgG, pro-
tein A (1 mg/ml), Z-VAD-fmk (20 mM) and CHX (2.5 mg/ml). Nuclear
extracts were prepared as described previously (31), and EMSA analy-
ses were performed using a standard procedure with a high pressure
liquid chromatography-purified NF-kB-specific oligonucleotide (59-ATC
AGG GAC TTT CCG CTG GGG ACT TTC CG-39), end-labeled with
[32P]ATP. Finally, samples were separated by native polyacrylamide gel
electrophoresis in low ionic strength buffer. For supershift analyses, 10
ml of the nuclear extracts (1 mg/ml protein) were incubated on ice for 1 h
with 1 mg of polyclonal antibodies specific for p65, p50, and cRel (Santa
Cruz Biotechnology, Heidelberg, Germany). Then the formed complexes
were incubated with 2 ml of 53 binding buffer (500 mM KCl, 50 mM
Tris-HCl, pH 7.4, 25 mM MgCl2, 50% glycerol, 5 mM dithiothreitol) and
2 ml of poly(dI-dC) (2 mg/ml) in a final volume of 20 ml. NF-kB DNA-
binding activity was again analyzed by native polyacrylamide gel elec-
trophoresis and phosphorimaging (Storm 860; Amersham Pharmacia
Biotech, Freiburg, Germany).
RESULTS AND DISCUSSION
Most ligands of the TNF family are either membrane-bound
or proteolytically processed into soluble proteins. Evidence sug-
gests that artificial cross-linking of soluble ligands mimics the
distinct biological activities of the corresponding membrane-
bound ligands. For example, we have recently shown that the
cytotoxic activity of FLAG-tagged human Fas ligand (sFasL),
was increased by .1000-fold in response to cross-linking with
the anti-FLAG monoclonal antibody M2. Notably, this in-
creased activity was comparable with the cytotoxic potency of
membrane-bound FasL (32). Further, activation of TNF-R2-de-
pendent signaling pathways by soluble FLAG-tagged TNF was
strongly increased by multimerization of this ligand by the
anti-FLAG monoclonal antibody M2. In accordance with that,
we have previously shown that membrane-bound, but not sol-
uble TNF, is the prime activating ligand for TNF-R2 (33, 34),
suggesting that cross-linked and membrane-bound ligands
have analogous effects on this receptor. Using various cell lines
we have therefore tested whether a recombinant soluble FLAG-
tagged form of TRAIL (sTRAIL) required cross-linking for its
activity.
We found that several cell lines, e.g. Jurkat and Kym-1,
designated in the following as group I cells, were killed by
physiological amounts (,200 ng/ml) of sTRAIL only in the
presence of secondary cross-linking by the anti-FLAG mono-
clonal antibody M2 (Fig. 1A). However, we also identified a
second set of cell lines designated in the following as group II
cells that were efficiently killed by non-cross-linked sTRAIL
(HeLa, HepG2, HT1080, and KB; Fig. 1A). The group II cell
lines Hela and KB were also tested with respect to the cross-
linking requirements of sTRAIL for non-apoptotic signaling. As
shown in Fig. 1, cross-linked and non-cross-linked sTRAIL both
have a comparable capacity to induce IL-6 production (Fig. 1B)
and elicited comparable NF-kB activation in a reporter gene
assay (Fig. 1C). The magnitude of NF-kB activation and IL-6
FIG. 2. A, protein A cross-linking enhanced the agonistic capacity of
anti-TRAIL-R1 and -R2 IgG. HepG2 cells were incubated overnight
with the indicated concentration of anti-TRAIL-R1 IgG and anti-
TRAIL-R2 IgG, respectively, with (filled bars) or without (open bars)
previous aggregation with protein A in the presence of 2.5 mg/ml CHX.
Cell viability was measured by crystal violet staining. In addition, HeLa
cells were treated in the same way with the anti-TRAIL-receptor IgGs
in the presence of 2.5 mg/ml CHX and 10 mM Z-VAD-fmk, and superna-
tants were analyzed for production of IL-6. B, cytotoxic effects of anti-
TRAIL-R1 IgG and anti-TRAIL-R2 IgG. Various cell lines were incu-
bated overnight with protein A cross-linked anti-TRAIL-R1 IgG (filled
bars) or anti-TRAIL-R2 IgG (hatched bars) or were left untreated (open
bars). The next day, cell viability was determined by the MTT assay
(Jurkat, Kym-1) or by staining with crystal violet (HeLa, KB, HepG2,
HT1080). To allow induction of apoptosis, HepG2, HeLa, KB, or HT1080
cells were treated in the presence of 2.5 mg/ml CHX. C, Kym-1 cells were
treated with anti-TRAIL-R1 or anti-TRAIL-R2 IgG (aTR1-IgG or aTR2-
IgG, respectively; 200 ng/ml) and protein A (1 mg/ml) with Z-VAD-fmk
(ZVAD, 20 mM). After 3 h, cells were harvested and analyzed for NF-kB
activation by EMSA. D, HeLa cells were treated as indicated with,
anti-TRAIL-R1 and anti-TRAIL-R2 IgG (200 ng/ml), protein A (1 mg/
ml), CHX (2.5 mg/ml), and Z-VAD-fmk (20 mM) for 3 h. As a control, cells
were also treated with 10 ng/ml TNF for 30 min. Supershift analyses
were performed as described under “Experimental Procedures.” Super-
shifted complexes of the NF-kB oligonucleotide and p65, p50, or cRel,
respectively, are indicated by arrows.
FIG. 3. TRAIL-R2 but not TRAIL-R1 signals JNK activation. A,
cell lysates were prepared from Kym-1, Jurkat, HeLa, and HepG2 cells
that had been stimulated for 4 h with protein A cross-linked (1 mg/ml)
anti-TRAIL-R1 IgG and anti-TRAIL-R2 IgG, each at 200 ng/ml in the
absence of CHX. For control purposes lysates from cells treated with
protein A and non-relevant IgG were also analyzed. JNK activity was
measured by immunocomplex kinase assay with GSTzc-Jun-(1–79) as a
substrate. B, dose dependence of anti-TRAIL-R2 IgG-induced JNK ac-
tivation. Kym-1, Jurkat, HeLa, and HepG2 cells were stimulated with
the indicated concentrations of protein A cross-linked anti-TRAIL-R2
IgG for 4 h, and lysates were analyzed for JNK activity by immuno-
complex kinase assays.
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production induced by cross-linked and non-cross-linked
sTRAIL was similar to that obtained by TNF stimulation (data
not shown). In all group II cells investigated, TRAIL-induced
apoptosis and activation of NF-kB were dependent on the pres-
ence of CHX. Activation of the NF-kB pathway is inhibited by
caspase-dependent mechanisms during apoptosis (35–38).
Thus, TRAIL-induced activation of NF-kB was therefore only
observed in group II cells when in addition to CHX a caspase
inhibitor (Z-VAD-fmk) was present (data not shown). However,
in group I cells, NF-kB activation was found in the absence of
CHX, provided that apoptosis was again inhibited by Z-VAD-
fmk (data not shown). Notably, when we analyzed TRAIL-
mediated JNK activation in group I (Kym-1) and II cells
(HeLa), we found in both cell lines a requirement for cross-
linked sTRAIL (Fig. 1D). As already outlined above, in group II
cell lines, sTRAIL activated NF-kB only in the presence of
CHX/Z-VAD-fmk and induced cell death only if CHX was pres-
ent. However, activation of the JNK pathway by cross-linked
TRAIL occurred in the absence of CHX and was therefore not
linked to cell death.
To analyze whether the requirement for cross-linked sTRAIL
correlated with a differential utilization of TRAIL-R1 and
TRAIL-R2, we reexamined the cells described above using pu-
rified IgG fractions of agonistic TRAIL-R1- and TRAIL-R2-
specific antisera. The agonistic activity of anti-TRAIL-R1 IgG
and anti-TRAIL-R2 IgG, respectively, was significantly in-
FIG. 4. A, analysis of TRAIL receptor
expression on various cell lines by FACS.
B, effect of CHX on the killing of Kym-1
cells by cross-linked and non-cross-linked
sTRAIL. Kym-1 cells were cultured over-
night in 96-well plates. Cells were then
incubated for additional 18 h with the
indicated concentrations of cross-linked
(circles) and non-cross-linked (squares)
sTRAIL in the presence (filled symbol) or
absence (open symbol) of 2.5 mg/ml CHX.
Cell viability was measured by the MTT
assay. C, Kym-1 cells were treated with
anti-TRAIL-R1 IgG (200 ng/ml), protein A
(1 mg/ml), and Z-VAD-fmk (ZVAD, 20 mM)
in the presence or absence of 2.5 mg/ml
CHX. After 3 h, cells were harvested and
analyzed for NF-kB activation with EMSA.
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creased upon aggregation with protein A, with respect to death
induction and up-regulation of IL-6 production (Fig. 2A). At the
concentrations used in this study (,200 ng/ml) the IgG frac-
tions were not cross-reactive. Using the agonist anti-TRAIL-
receptor IgGs, we found that group I cells were exclusively
killed by anti-TRAIL-R2 IgG, whereas group II cells were sen-
sitive for stimulation with both anti-TRAIL-R1 and anti-
TRAIL-R2 IgG (Fig. 2B). Moreover, in the group II cell line
HeLa, both IgG preparations induced NF-kB activation
whereas in the group I cell line Kym-1 only anti-TRAIL-R2 IgG
but not anti-TRAIL-R1 IgG was able to activate NF-kB (Fig. 2,
C and D). Again in HeLa cells treatment with CHX and Z-VAD-
fmk was necessary to elicit the NF-kB response, whereas in
Kym-1 cells NF-kB activation only required inhibition of the
apoptotic pathway. Supershift analyses in HeLa cells revealed
that TRAIL-R1 and TRAIL-R2 engaged the NF-kB family
members p65, p50, and cRel in a comparable manner to
TNF-R1 (Fig. 2D). In group I as well as in group II cell lines the
first signs of NF-kB DNA-binding activity were detectable 1 to
2 h upon TRAIL receptor stimulation whereas TNF induced
NF-kB DNA-binding activity within 15–30 min. NF-kB DNA-
binding activity induced by both cytokines sustained for sev-
eral hours in both type of cells (data not shown). Importantly,
the JNK pathway was triggered in group I and II cell lines by
stimulation of TRAIL-R2 but not by stimulation of TRAIL-R1
(Fig. 3). To our knowledge, this is the first reported difference
in the signaling capacities of the two death domain-containing
TRAIL receptors.
Based on these results, it is evident that group II cells must
co-express both death domain-containing TRAIL receptors,
whereas group I cells either express no TRAIL-R1 or this mol-
ecule was silenced in some way under the conditions used in
our study. As shown in Fig. 4A, all cells investigated with the
exception of Jurkat cells were positive for TRAIL-R1 and
TRAIL-R2 expression in FACS analysis. In addition, with the
exception of Jurkat and HeLa cells, all investigated cell lines
express at least one of the TRAIL decoy receptors (TRAIL-R3,
TRAIL-R4). Nevertheless, in all cases the expression of the
decoy receptors was rather low compared with TRAIL-R1 and
TRAIL-R2 expression, which is consistent with the TRAIL-
sensitivity of these cell lines. In light of the expression data it
became clear that the group I cell line Jurkat did not respond
to anti-TRAIL-R1 IgG (or non-cross-linked sTRAIL) as
TRAIL-R1 is not significantly expressed on this cell line. How-
ever, in the case of the TRAIL-R1-expressing Kym-1 cell line, it
is obvious that TRAIL-R1 signaling has to be negatively regu-
lated (by an unknown mechanism). As in group II cells, because
low concentrations of the metabolic inhibitor CHX were neces-
sary to allow TRAIL-R1-mediated NF-kB activation and induc-
tion of cell death, we tested the signaling capacity of TRAIL-R1
in this group I cell line also in the presence of CHX. In fact,
Kym-1 cells became sensitive to anti-TRAIL-R1 IgG (data not
shown) and non-cross-linked sTRAIL (Fig. 4B) in the presence
of CHX. Moreover, whereas in the absence of CHX only stim-
ulation of TRAIL-R2 activated the NF-kB pathway (see Fig.
2C), stimulation of TRAIL-R1 also induced NF-kB activation
provided that CHX and Z-VAD-fmk were added (see Fig. 4C).
Because of the high cytotoxicity of CHX, putative effects of this
compound on TRAIL receptor-induced apoptosis, cells could not
be examined in Jurkat cells (data not shown). Our observations
may suggest the existence of two CHX-sensitive factors or
pathways. The first one is active in group II cells to prevent
TNF-, FasL-, and TRAIL-mediated cell death. The second li-
gand may specifically block TRAIL-R1 pathways in group I
cells. It is noteworthy that TRAIL-R2-mediated JNK activation
occurred in group I and group II cells in the absence of CHX,
clearly demonstrating the ability of TRAIL-R2 to transmit spe-
cific signals in the absence of cell death. It is possible that
TRAIL-R2 is also important for non-apoptotic signal transduc-
tion. This may involve the activation of c-Jun and other JNK-
or NF-kB related downstream responses, which regulate pro-
liferation and differentiation in normal cells. The apoptotic
function of TRAIL-R2, which is cryptic in normal cells, may
only be dominantly revealed in transformed cells. Although
JNK was only activated via endogenous TRAIL-R2 but not
endogenous TRAIL-R1, we also noted that transient overex-
pression of both TRAIL-R1 and TRAIL-R2 activated JNK in a
ligand-independent fashion (data not shown). We can therefore
not completely exclude the possibility that endogenous
TRAIL-R1 might activate JNK in some circumstances.
In conclusion, our data suggest that TRAIL-R1 responds to
cross-linked and non-cross-linked TRAIL to signal NF-kB acti-
vation and apoptosis, whereas TRAIL-R2 signals NF-kB acti-
vation, apoptosis, and JNK activation in response to cross-
linked TRAIL only. We hypothesize that the requirement of
cross-linked sTRAIL reflects the requirement of TRAIL-R2 for
membrane-bound TRAIL.
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